Serving Southwest Florida — Alzheimer’s Care Alliance
Helpline: 800.272.3900 Find Local Resources →
Research & Treatments

Kisunla® (donanemab)

Kisunla is an FDA-approved treatment for certain people in the early symptomatic stages of Alzheimer’s disease. It targets amyloid in the brain and is intended to slow disease…

Browse Research & Treatments topics
Research & Treatments Overview
Treatment Options
Treatment OverviewLeqembiKisunlaAgitation TreatmentWhat to Expect With TreatmentMedicare Coverage
Clinical Research
Intercoastal Clinical ResearchCurrent Sarasota ResearchResearch Information / ReferralClinical References
FDA-Approved Treatment

Kisunla® (donanemab)

Kisunla is an FDA-approved treatment for certain people in the early symptomatic stages of Alzheimer’s disease. It targets amyloid in the brain and is intended to slow disease progression rather than cure or reverse Alzheimer’s disease.

Patients need specialist evaluation and monitoring because treatment can have important risks, including ARIA and infusion-related reactions.

FDA: Kisunla Approval Information FDA: Kisunla Drug Information